What are your expectations of the GIPRa/GLP-1Ra in development on efficacy and safety based on the phase 2 data (such as AMG133/Maritide)? What are the key advantages and disadvantages of MariTide vs. the SOC?

For AMG133/Maritide, do you think monthly dosing is feasible? Why or why not?

What do you think will be required for AMG133/Maritide to advance to phase 3? Why type of endpoints would likely make the investment palatable for the manufacturer?

How do you foresee the GIPRa/GLP-1Ra in development (such as AMG133/Maritide) being used in clinical practice for a specific patient segment and as part of a future obesity management algorithm?

What are your expectations for efficacy and safety for the GLP1R-GCGR in development, such as Survodutide?  What are the key advantages and disadvantages  vs. the SOC?

In your opinion, which events/advances will shape the obesity market in the coming ~5 years, and how?  

For drugs in phase 2 and early phase 3 development, how important is the quality of weight loss for HCPs and patients? Which endpoints should be considered when talking about the quality of weight loss?

In your opinion, who do you consider to be your key manufacturers in this space in the future, and which are the “key upcoming assets to watch” and why?

Overall, how do you think the obesity market will look in the next 5-7 years in terms of patient segments? It looks like the market is increasingly being segmented based on the benefit of the AOMs on ORCs – do you foresee any other segmentation possibilities?